Akso Health Group stock
AHGNASDAQHealthcareISIN US98422P1084
36Score 36 out of 100, Weak
Price and trend
54 / 100
Price history
−11% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 11% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 46% below its 52-week high. Largest decline in 9 years: 100% (November 2017 to July 2023).
Chart figures for advanced users
- SMA 50$1.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.50
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.69
- The lowest closing price of the last twelve months.
- Resistance$2.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Akso Health Group belongs to the Medical (Distribution) industry (China) and, with a market value of $1.15B, is number 13 of 17 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2026 it reported revenue of $13.83M (down 6.4% year on year) and a loss of $18.67M.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 610 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Loss-makingLoss of $28.65M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 97% a year over the last 12 months.Stability 69
- Negative free cash flowFree cash flow −$106.41M over the last 12 months.Fundamentals 20
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 34 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue fell 6.4% on the prior year. Revenue has grown strongly since 2024, at around 139% per year. From 2024 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2024 are not measured.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 0%, operating −29%, net −135%. Last 12 months: net −100%. From 2024 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2024 are not measured.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 2 Dec 2026in 20 days
- Last reported
- 16 Jun 2026
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 4.020.0%
- Revenue
- $108.28M0.0%
- Earnings per share
- −0.120.0%
- Revenue
- $66.57M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Akso Health Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger and next smaller companies by market value
- Asker Healthcare GroupASKER.ST $2.87B61
- Sopharma ADSPH.WA $1.9B57
- Redcare PharmacyRDC.DE $1.6B47
- UnipharUPR.IR $1.27B57
- DocMorrisDOCM.SW $1.14B39
- ArjoARJO-B.ST $927.89M58
- Neuca S.a.NEU.WA $788.51M59
- MediosILM1.DE $322.4M50
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.